AUTHOR=Baldoni Stefano , Del Papa Beatrice , De Falco Filomena , Dorillo Erica , Sorrentino Carlo , Rompietti Chiara , Adamo Francesco Maria , Nogarotto Manuel , Cecchini Debora , Mondani Elena , Silva Barcelos Estevao Carlos , Moretti Lorenzo , Mameli Maria Grazia , Fabi Bianca , Sorcini Daniele , Stella Arianna , Giancola Raffaella , Guardalupi Francesco , Ulbar Francesca , Plebani Sara , Guarente Valerio , Rosati Emanuela , Di Nicola Marta , Marchioni Michele , Di Ianni Mauro , Sportoletti Paolo 

TITLE=NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.668573

DOI=10.3389/fonc.2021.668573

ISSN=2234-943X

ABSTRACT=<p>NOTCH1 mutations and deregulated signal have been commonly found in chronic lymphocytic leukemia (CLL) patients. Whereas the impact of <italic>NOTCH1</italic> mutations on clinical course of CLL has been widely studied, the prognostic role of NOTCH1 activation in CLL remains to be defined. Here, we analyzed the activation of NOTCH1/NOTCH2 (ICN1/ICN2) and the expression of JAGGED1 (JAG1) in 163 CLL patients and evaluated their impact on TTFT (Time To First Treatment) and OS (Overall Survival). NOTCH1 activation (ICN1+) was found in 120/163 (73.6%) patients. Among them, 63 (52.5%) were <italic>NOTCH1</italic> mutated (ICN1+/mutated) and 57 (47.5%) were <italic>NOTCH1</italic> wild type (ICN1+/WT). ICN1+ patients had a significant reduction of TTFT compared to ICN1-negative (ICN1−). In the absence of <italic>NOTCH1</italic> mutations, we found that the ICN1+/WT group had a significantly reduced TTFT compared to ICN1− patients. The analysis of <italic>IGHV</italic> mutational status showed that the distribution of the mutated/unmutated <italic>IGHV</italic> pattern was similar in ICN1+/WT and ICN1− patients. Additionally, TTFT was significantly reduced in ICN1+/ICN2+ and ICN1+/JAG1+ patients compared to ICN1−/ICN2− and ICN1−/JAG1− groups. Our data revealed for the first time that <italic>NOTCH1</italic> activation is a negative prognosticator in CLL and is not correlated to <italic>NOTCH1</italic> and <italic>IGHV</italic> mutational status. Activation of NOTCH2 and JAGGED1 expression might also influence clinical outcomes in this group, indicating the need for further dedicated studies. The evaluation of different NOTCH network components might represent a new approach to refine CLL risk stratification.</p>